Lobe Sciences Ltd. (CSE:LOBE)
Canada · Delayed Price · Currency is CAD 0.0900
+0.0100 (12.50%)
Aug 10, 2026, 1:44 PM EST
Lobe Sciences Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
24.65M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | - | - | - |
| Aug 31, 2024 | 136.21K | -704.33K | -83.80% |
| Aug 31, 2023 | 840.53K | - | - |
| Aug 31, 2022 | - | - | - |
| Aug 31, 2021 | - | - | - |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Lobe Sciences News
- 5 days ago - Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders - Accesswire
- 4 weeks ago - Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026 - Accesswire
- 2 months ago - Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares - Accesswire
- 2 months ago - Lobe Sciences Announces Proposed Shares for Debt Transaction - Accesswire
- 3 months ago - Lobe Sciences Ltd. Announces Participation in the D. - Accesswire
- 3 months ago - Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress - Accesswire
- 3 months ago - Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders - Accesswire
- 3 months ago - Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services - Accesswire